These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37169576)

  • 21. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
    J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
    van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
    Boguniewicz M; Beck LA; Sher L; Guttman-Yassky E; Thaçi D; Blauvelt A; Worm M; Corren J; Soong W; Lio P; Rossi AB; Lu Y; Chao J; Eckert L; Gadkari A; Hultsch T; Ruddy M; Mannent LP; Graham NMH; Pirozzi G; Chen Z; Ardeleanu M
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1212-1223.e6. PubMed ID: 33453450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of dupilumab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis.
    Siegfried EC; Igelman S; Jaworski JC; Antaya RJ; Cordoro KM; Eichenfield LF; Levy ML; Paller AS
    Pediatr Dermatol; 2019 Jan; 36(1):172-176. PubMed ID: 30675938
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease.
    Alegre-Bailo A; Sánchez-Gilo A; Gonzalo González I; Vicente Martín FJ
    Australas J Dermatol; 2024 Feb; 65(1):63-66. PubMed ID: 37929636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case series of dupilumab-treated allergic contact dermatitis patients.
    Goldminz AM; Scheinman PL
    Dermatol Ther; 2018 Nov; 31(6):e12701. PubMed ID: 30246906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
    Wechsler ME; Klion AD; Paggiaro P; Nair P; Staumont-Salle D; Radwan A; Johnson RR; Kapoor U; Khokhar FA; Daizadeh N; Chen Z; Laws E; Ortiz B; Jacob-Nara JA; Mannent LP; Rowe PJ; Deniz Y
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2695-2709. PubMed ID: 35636689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab: A New Paradigm for the Treatment of Allergic Diseases.
    Sastre J; Dávila I
    J Investig Allergol Clin Immunol; 2018 Jun; 28(3):139-150. PubMed ID: 29939132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Dupilumab for Severe Atopic Dermatitis Co-occurring With Asthma in a Real-World Setting.
    Pose K; Laorden D; Hernández N; Villamañán E; Quirce S; Domínguez-Ortega J
    J Investig Allergol Clin Immunol; 2023 Jun; 33(3):217-219. PubMed ID: 37318773
    [No Abstract]   [Full Text] [Related]  

  • 32. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
    Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
    Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Effects Under Th2 Biologics (Dupilumab and Tezepelumab) in a Patient with Severe Asthma and Atopic Dermatitis.
    Suhling H; Hinze CA; Welte T; Werfel T; Traidl S
    Respiration; 2023; 102(12):1016-1019. PubMed ID: 38008067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

  • 36. Dupilumab for treatment of atopic dermatitis.
    Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dupilumab for the treatment of asthma.
    Pelaia C; Vatrella A; Gallelli L; Terracciano R; Navalesi P; Maselli R; Pelaia G
    Expert Opin Biol Ther; 2017 Dec; 17(12):1565-1572. PubMed ID: 28990423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.